Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study

Part of paid clinical trials in Hillsborough, New Jersey.

Sponsor
Id Care
Study ID
NCT03364725
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 30 Years
Healthy Volunteers
Not accepted

Interventions

  • Glecaprevir-pibrentasvir — DRUG
    Glecaprevir-pibrentasvir will be dispensed to 30 patients recently detoxed off heroin in an acute detox center.

Study Details

To demonstrate that colocation treatment of substance use disorder and Hepatitis C infection concurrently while proving addiction counselling will achieve increased duration of sobriety and elimination of Hepatitis C virus in study participants.

Key Dates

Start date
Jan 15, 2018
Status verified
Dec 2017
Primary completion
Sep 1, 2018
Completion
Mar 1, 2019

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Open Label Treatment Arm
    Treatment arm using Glecaprevir-pibrentasvir for treatment of all patients

Primary Outcome Measure

Cure rate of Hepatitis C Infection [ Time Frame: 12 weeks after treatment completion viral load measure ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
ID CAREHillsboroughNew Jersey08844
Ronald Nahass, MD
[email protected]
908-281-0221
Kathleen Seneca, MSN, APN
[email protected]
9082810221

Find similar trials in Hillsborough, NJ

By research site
ID CARE· Hillsborough, NJ

Related Studies